Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD.
We describe here the case of an adolescent who developed eosinophilic hepatitis during treatment for attention-deficit/hyperactivity disorder with lisdexamfetamine dimesylate (Vyvanse [Shire US Inc, Wayne, PA]). A 14-year-old boy presented to his primary care provider with abdominal pain and worsening jaundice. A diagnosis of hepatitis was made with biochemical markers, but evaluation failed to provide an etiology. Worsening hepatitis prompted hospitalization and initiation of steroids for presumed autoimmune hepatitis. A subsequent liver biopsy showed evidence of eosinophilic hepatitis. Known causes of eosinophilic hepatitis were ruled out, and a presumptive diagnosis of reaction to lisdexamfetamine dimesylate was made. Discontinuation of the medication led to resolution of the hepatitis and normalization of the liver biopsy. To our knowledge, this is the first report of hepatic injury attributed to lisdexamfetamine dimesylate.
Hood
Brandy
B
Division of Pediatric Gastroenterology, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Nowicki
Michael J
MJ
D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology*; D003913:Dextroamphetamine / Q000009:adverse effects* / Q000627:therapeutic use; D004802:Eosinophilia / Q000139:chemically induced*; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate; D008297:Male
D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine